Another combination study
https://www.sciencedirect.com/science/a ... 2622001168
Disease modification in MF
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Re: Disease modification in MF
Note AbbVie again. Navitoclax + Ruxolitinib + Imetelstat (interesting combination). AbbVie is serious about combinations. Also TELOMERE (AbbVie & Geron)
-----------------------------
Furthermore, the overall survival benefit observed in those with an improvement in fibrosis or a reduction in variant allele frequency is suggestive of disease modification, implying the therapeutic potential of adding navitoclax to ruxolitinib for patients with myelofibrosis who had disease progression or suboptimal response to ruxolitinib monotherapy.
Funding
AbbVie.
-----------------------------
Furthermore, the overall survival benefit observed in those with an improvement in fibrosis or a reduction in variant allele frequency is suggestive of disease modification, implying the therapeutic potential of adding navitoclax to ruxolitinib for patients with myelofibrosis who had disease progression or suboptimal response to ruxolitinib monotherapy.
Funding
AbbVie.